Thyroid Cancer (Papillary and Follicular Carcinoma)

    Actionable Target Abnormality Prevalence Clinical Experience with Targeted Agent
    VEGFR2 N/A N/A Lenvatinib (VEGFR2 inhibitor) (FDA approved for differentiated thyroid cancer):
    • Phase 3: CR 1.5%, PR 63.2%, SD 23%, PD 6.9%, PFS 18.3 mo (1)
    Other topics in Targets by Organ Site